| Literature DB >> 28964959 |
Kenko Azuma1, Tomohiro Umezu2, Satoshi Imanishi1, Michiyo Asano2, Seiichiro Yoshizawa2, Seiichiro Katagiri2, Kazuma Ohyashiki2, Junko H Ohyashiki3.
Abstract
Bone marrow mesenchymal stromal cells (MSCs), which support proliferation and differentiation of hematopoietic stem cells, may play a crucial role in the pathogenesis of myeloid neoplasms. To determine whether MSCs in myeloid neoplasms harbor distinct somatic mutations that may affect their function, we used a targeted gene sequencing panel containing 50 myeloid neoplasm-associated genes with coverage of ≥500. We compared the genetic alterations between MSCs and bone marrow hematopoietic (BM) cells from patients with acute leukemia (n=5) or myelodysplastic syndrome (MDS, n=5). Non-synonymous somatic mutations, such as DNMT3A-R882H and FLT3-D835Y, were only detected in BM cells with high allelic frequency. We found several non-synonymous genetic variants overlapping BM cells and MSCs, including TP53 and ASXL1, partially owing to the heterogenous cell fraction of MSC samples and lineage fidelity. We also found MSC-specific genetic variants with very low allelic frequency (7% to 8%), such as NF1-G2114D and NF1-G140. Further studies in large cohorts are needed to clarify the molecular properties of MSCs including age-related genetic alterations by targeted deep sequencing.Entities:
Keywords: Bone marrow mesenchymal stromal cells; Genetic variants; Myeloid malignancies; Targeted deep sequencing
Mesh:
Year: 2017 PMID: 28964959 DOI: 10.1016/j.leukres.2017.09.008
Source DB: PubMed Journal: Leuk Res ISSN: 0145-2126 Impact factor: 3.156